StemSight secures new patents for scalable induced pluripotent stem cells-derived limbal stem cells, boosting STE-101’s path to off-the-shelf limbal stem cell deficiency therapy and upcoming Series A.
Abigail Lewis, Content Intern
Advertisement
Contact me!
Email: [email protected]
Articles by Abigail Lewis, Content Intern
The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Port Delivery System Therapies in Retinal Vascular Diseases
2
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
3
Polyendocrine metabolic ovarian syndrome: looking past the reproductive system to the eye
4
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
5